A novel fungal molecule, acremopyrone A, shows potential as a safer, more effective way to control blood sugar after meals, offering new hope in antidiabetic drug development.
Researchers have identified a new fungal compound that may offer a fresh route for controlling blood sugar after meals, according to a paper in The Journal of Antibiotics. The molecule, named acremopyrone A, was isolated from the soil-dwelling fungus Acremonium persicinum strain 3.2858 and showed significant activity against alpha-glucosidase, an enzyme involved in breaking down carbohydrates into glucose. The study suggests the compound could serve as a lead for future antidiabetic drug design.
The discovery adds to long-running interest in natural products as a source of medicines. Soil fungi have already yielded major drugs, and Acremonium species in particular have a history of producing biologically active compounds. In this case, the researchers used standard natural-products methods to grow the fungus, extract its metabolites and separate the active fraction before identifying the new chemical.
To determine the structure of acremopyrone A, the team relied on nuclear magnetic resonance and high-resolution electrospray ionisation mass spectrometry. Those analyses showed that the compound is a previously unreported alpha-pyrone derivative, a class of small molecules that has attracted attention for a range of biological effects. The study also examined how the compound interacts with its target using enzyme kinetics and molecular docking.
The kinetic work indicated mixed-type inhibition, meaning acremopyrone A can bind to both the free enzyme and the enzyme-substrate complex. That matters because it suggests the compound acts differently from existing alpha-glucosidase inhibitors such as acarbose, miglitol and voglibose, which are widely used but can cause troublesome gastrointestinal side effects. A new scaffold with a different binding pattern could give medicinal chemists more room to improve both potency and tolerability.
The findings remain early-stage, and acremopyrone A is far from becoming a medicine. But the study adds another candidate to the search for better ways to blunt post-meal glucose spikes, which are central to diabetes management. It also reinforces a broader point in drug discovery: some of the most interesting chemistry still comes from overlooked microbes in ordinary soil.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
